Comparative Pharmacology
Head-to-head clinical analysis: FML FORTE versus PRED FORTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML FORTE versus PRED FORTE.
FML FORTE vs PRED FORTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorometholone is a synthetic corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in suppression of inflammation, immune response, and fibroblast proliferation.
Corticosteroid that binds to glucocorticoid receptors, causing inhibition of phospholipase A2, arachidonic acid release, and synthesis of inflammatory mediators. Reduces inflammation by suppressing leukocyte infiltration and cytokine production.
1 drop of 0.25% ophthalmic suspension in the conjunctival sac of the affected eye(s) every 4 hours. In severe conditions, 1 drop every 2 hours initially, taper as response is achieved.
1-2 drops in the conjunctival sac every 1-2 hours during the day and every 4 hours at night initially, then taper to every 4-8 hours as inflammation resolves. Severe cases may require hourly dosing.
None Documented
None Documented
Plasma terminal elimination half-life is approximately 3-4 hours (range 2-6 hours) for fluorometholone alcohol; clinical effects may persist longer due to tissue retention.
2-3 hours (terminal) after IV administration; for topical ophthalmic use, systemic half-life is similar but local ocular half-life is prolonged due to corneal reservoir.
Eliminated primarily via hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 60-70%, with about 30-40% excreted in feces via bile.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for approximately 80% of elimination, with biliary/fecal elimination <20%.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid